AGT and metabolic dysfunction-associated steatotic liver disease: Animal models have also suggested a potential role for angiotensin II in the progression of NAFLD to hepatic fibrosis [66], and the use of angiotensin II type 1 receptor antagonists has been shown to reduce this progression [67].